Evolent Health faces volatility with missed targets and 2024 guidance cuts. Click here for a full investment analysis of EVH ...

Full Year 2024 Results Key Financial Results Revenue: US$2.55b (up 30% from FY 2023).

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Evolent Health (EVH – Research Report). The ...

Citizens JMP raised the firm’s price target on Evolent Health (EVH) to $13 from $12 and keeps an Outperform rating on the shares. Evolent’s Q4 ...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings tomorrow afternoon. Here’s what investors should ...

NYSE EVH opened at $10.44 on Friday. Evolent Health has a one year low of $9.45 and a one year high of $35.00. The stock has a 50-day moving average of $10.75 and a 200 day moving average of $18. ...

Shares of NYSE EVH opened at $10.44 on Friday. Evolent Health has a 1-year low of $9.45 and a 1-year high of $35.00. The company has a 50-day moving average of $10.75 and a two-hundred day moving ...

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively.Net loss ...

Evolent Health Inc. (EVH) has disclosed a new risk, in the Technology category. Evolent Health Inc. faces significant risks associated with its ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...